BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008;336:813-6. [PMID: 18334527 DOI: 10.1136/bmj.39507.551644.BE] [Cited by in Crossref: 121] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE. Drug-induced atrial fibrillation. Drugs 2012;72:1617-30. [PMID: 22834678 DOI: 10.2165/11633140-000000000-00000] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
2 Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010;25:91-7. [PMID: 19580467 DOI: 10.1359/jbmr.090704] [Cited by in Crossref: 102] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
3 Kang JH, Keller JJ, Lin HC. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 2012;23:2551-7. [PMID: 22270858 DOI: 10.1007/s00198-012-1894-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chapurlat RD. Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture. Ther Clin Risk Manag 2009;5:169-75. [PMID: 19536314 DOI: 10.2147/tcrm.s3768] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
5 Piper PK Jr, Gruntmanis U. Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging 2009;4:289-303. [PMID: 19750231 DOI: 10.2147/cia.s4295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
6 Barrett-Connor E, Swern AS, Hustad CM, Bone HG, Liberman UA, Papapoulos S, Wang H, de Papp A, Santora AC. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012;23:233-45. [PMID: 21369791 DOI: 10.1007/s00198-011-1546-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
7 Kirchmayer U, Sorge C, Sultana J, Lapi F, Onder G, Agabiti N, Cascini S, Roberto G, Corrao G, Vitale C, Lucenteforte E, Mugelli A, Davoli M. Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy. Ther Adv Drug Saf 2019;10:2042098619838138. [PMID: 31057787 DOI: 10.1177/2042098619838138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int 2013;24:271-7. [PMID: 23152093 DOI: 10.1007/s00198-012-2213-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
9 Erichsen R, Christiansen CF, Frøslev T, Jacobsen J, Sørensen HT. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Br J Cancer 2011;105:881-3. [PMID: 21878939 DOI: 10.1038/bjc.2011.338] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
10 Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 2010;28:4898-905. [PMID: 20940190 DOI: 10.1200/JCO.2010.28.7524] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
11 Durgia H, Sahoo J, Kamalanathan S, Palui R, Sridharan K, Raj H. Role of bisphosphonates in the management of acute Charcot foot. World J Diabetes 2018; 9(7): 115-126 [PMID: 30079147 DOI: 10.4239/wjd.v9.i7.115] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009;4:e4720. [PMID: 19266096 DOI: 10.1371/journal.pone.0004720] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
13 Fazmin IT, Huang CL, Jeevaratnam K. Bisphosphonates and atrial fibrillation: revisiting the controversy. Ann N Y Acad Sci 2020;1474:15-26. [PMID: 32208537 DOI: 10.1111/nyas.14332] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Pazianas M, Cooper C, Wang Y, Lange JL, Russell RG. Atrial fibrillation and the use of oral bisphosphonates. Ther Clin Risk Manag 2011;7:131-44. [PMID: 21479144 DOI: 10.2147/TCRM.S17899] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Arslan C, Aksoy S, Dizdar O, Dede DS, Harputluoglu H, Altundag K. Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer 2011;19:425-30. [PMID: 20358384 DOI: 10.1007/s00520-010-0868-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
16 Herrera L, Leal I, Lapi F, Schuemie M, Arcoraci V, Cipriani F, Sessa E, Vaccheri A, Piccinni C, Staniscia T, Vestri A, Di Bari M, Corrao G, Zambon A, Gregori D, Carle F, Sturkenboom M, Mazzaglia G, Trifiro G. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. Osteoporos Int 2015;26:1499-506. [PMID: 25752621 DOI: 10.1007/s00198-014-3020-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
17 Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis. 2010;1:115-128. [PMID: 23251734 DOI: 10.1177/2040622310374783] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
18 Vondracek SF, Linnebur SA. Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging 2009;4:121-36. [PMID: 19503775 DOI: 10.2147/cia.s4965] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
19 Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;6:325-43. [PMID: 20668715 DOI: 10.2147/tcrm.s8054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 28] [Article Influence: 0.3] [Reference Citation Analysis]
20 Silverman SL. Osteoporosis therapies: evidence from health-care databases and observational population studies. Calcif Tissue Int 2010;87:375-84. [PMID: 20725827 DOI: 10.1007/s00223-010-9400-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
21 Shaker JL. Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management. Ther Adv Musculoskelet Dis 2009;1:107-25. [PMID: 22870432 DOI: 10.1177/1759720X09351779] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
22 Rahmani P, Morin S. Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ 2009;181:815-20. [PMID: 19841053 DOI: 10.1503/cmaj.080709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ahern TP, Lash TL, Sørensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res 2008;10:R102. [PMID: 19055760 DOI: 10.1186/bcr2205] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
24 Fuggle NR, Cooper C, Harvey NC, Al-Daghri N, Brandi ML, Bruyere O, Cano A, Dennison EM, Diez-Perez A, Kaufman JM, Palacios S, Prieto-Alhambra D, Rozenberg S, Thomas T, Tremollieres F, Rizzoli R, Kanis JA, Reginster JY. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs 2020;80:1537-52. [PMID: 32725307 DOI: 10.1007/s40265-020-01364-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
25 Park SY, Kim SH, Kim TY, Lee YK, Ha YC, Jang S, Ahn SH, Kim HY. Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea. J Korean Med Sci 2021;36:e186. [PMID: 34254473 DOI: 10.3346/jkms.2021.36.e186] [Reference Citation Analysis]
26 Rousière M. [The importance of taking care of osteoporosis]. Presse Med 2011;40:900-9. [PMID: 21493035 DOI: 10.1016/j.lpm.2011.02.025] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Friis S, Karagas MR, Sørensen HT. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009;100:200-5. [PMID: 19034275 DOI: 10.1038/sj.bjc.6604796] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
28 Erichsen R, Christiansen CF, Mehnert F, Weiss NS, Baron JA, Sørensen HT. Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study. Intern Emerg Med 2012;7:431-8. [PMID: 21968511 DOI: 10.1007/s11739-011-0701-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
29 Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009;84:632-7; quiz 638. [PMID: 19567717 DOI: 10.1016/S0025-6196(11)60752-0] [Cited by in Crossref: 211] [Cited by in F6Publishing: 122] [Article Influence: 16.2] [Reference Citation Analysis]
30 Majumdar SR. Oral bisphosphonates and atrial fibrillation. BMJ 2008;336:784-5. [PMID: 18334526 DOI: 10.1136/bmj.39513.481065.80] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
31 Tisdale JE, Allen MR, Overholser BR, Jaynes HA, Kovacs RJ. Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements. J Cardiovasc Electrophysiol 2015;26:671-7. [PMID: 25684326 DOI: 10.1111/jce.12641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
32 Lu YH, Rosner B, Chang G, Fishman LM. Twelve-Minute Daily Yoga Regimen Reverses Osteoporotic Bone Loss. Top Geriatr Rehabil 2016;32:81-7. [PMID: 27226695 DOI: 10.1097/TGR.0000000000000085] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011;71:791-814. [PMID: 21504254 DOI: 10.2165/11585470-000000000-00000] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
34 Jensen AØ, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. Validity of the recorded International Classification of Diseases, 10th edition diagnoses codes of bone metastases and skeletal-related events in breast and prostate cancer patients in the Danish National Registry of Patients. Clin Epidemiol 2009;1:101-8. [PMID: 20865091 DOI: 10.2147/clep.s5446] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
35 Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032-1045. [PMID: 18775204 DOI: 10.4065/83.9.1032] [Cited by in Crossref: 683] [Cited by in F6Publishing: 611] [Article Influence: 48.8] [Reference Citation Analysis]
36 John Wiley & Sons, Ltd. Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidem Drug Safe 2008;17:i-xvi. [DOI: 10.1002/pds.1491] [Reference Citation Analysis]
37 Schmidt M, Antonsen S, Hansen B, Møller J, Thordal C, Sørensen HT. Mortality following acute medical admission in Denmark: a feasibility study. Clin Epidemiol 2010;2:195-203. [PMID: 21042551 DOI: 10.2147/CLEP.S12171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
38 Yazici O, Aksoy S, Ucar O, Ozdemir N, Demir M, Sendur MA, Arik Z, Yaman S, Eren T, Uncu D, Zengin N. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis. Med Oncol 2013;30:609. [PMID: 23690271 DOI: 10.1007/s12032-013-0609-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int 2011;22:1037-45. [PMID: 20449570 DOI: 10.1007/s00198-010-1276-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
40 Kim SY, Kim MJ, Cadarette SM, Solomon DH. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 2010;12:R30. [PMID: 20170505 DOI: 10.1186/ar2938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
41 Serefoglu EC, Tandogdu Z. Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag 2010;6:219-23. [PMID: 20526439 DOI: 10.2147/tcrm.s7245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Thadani SR, Ristow B, Blackwell T, Mehra R, Stone KL, Marcus GM, Varosy PD, Cummings SR, Cawthon PM. Relationship of Bisphosphonate Therapy and Atrial Fibrillation/Flutter. Chest 2016;149:1173-80. [DOI: 10.1016/j.chest.2015.11.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
43 Demirtas D, Bilir C, Demirtas AO, Engin H. The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer. Clin Cases Miner Bone Metab 2017;14:35-9. [PMID: 28740523 DOI: 10.11138/ccmbm/2017.14.1.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
44 Frediani B, Cavalieri L, Cremonesi G. Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig 2009;29:359-79. [PMID: 19432497 DOI: 10.2165/00044011-200929060-00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
45 Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 2009;10:113. [PMID: 19772579 DOI: 10.1186/1471-2474-10-113] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
46 Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. Core Evid 2010;4:13-23. [PMID: 20694061 DOI: 10.2147/ce.s6011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
47 Rizzoli R, Reginster JY, Boonen S, Bréart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011;89:91-104. [PMID: 21637997 DOI: 10.1007/s00223-011-9499-8] [Cited by in Crossref: 122] [Cited by in F6Publishing: 102] [Article Influence: 11.1] [Reference Citation Analysis]